SAN FRANCISCO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data on a series of selective KAT6A degraders in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-)…
SAN FRANCISCO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data on a series of selective KAT6A degraders in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer models. The findings will be presented in a poster session at the 38th EORTC-NCI-AACR (ENA) Symposium, held November 18-20, 2026 in Barcelona, Spain.
Regula expands its identity document database to 17,000 templates from 254 countries and territories, strengthening global ID recognition and verification. ...
Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies ...
Imprivata-Umfrage: 38 Prozent der Belegschaft in der Produktion haben jeden Monat Probleme bei der Authentifizierung Imprivata-Umfrage: 38 Prozent der Belegschaft in der Produktion haben jeden Monat Probleme bei der Authentifizierung ...